Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction

M. A. ap Pfeffer, B. Claggett, E. F. Lewis, C. B. Granger, L. Kober, A. P. Maggioni, D. L. Mann, J. J. V. McMurray, J. -L. Rouleau, S. D. Solomon, P. G. Steg, O. Berwanger, M. Cikes, C. G. De Pasquale, C. East, A. Fernandez, K. Jering, U. Landmesser, R. Mehran, B. MerkelyF. Vaghaiwalla Mody, M. C. Petrie, I. Petrov, M. Schou, M. Senni, D. Sim, P. van der Meer, M. Lefkowitz, Y. Zhou, J. Gong, E. Braunwald

Research output: Contribution to journalArticleAcademicpeer-review

38 Citations (Scopus)

Abstract

BACKGROUND
In patients with symptomatic heart failure, sacubitril–valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting–enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking. METHODS We randomly assigned patients with myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both to receive either sacubitril–valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or ramipril (5 mg twice daily) in addition to recommended therapy. The primary outcome was death from cardiovascular causes or incident heart failure (outpatient symptomatic heart failure or heart failure leading to hospitalization), whichever occurred first. RESULTS
A total of 5661 patients underwent randomization; 2830 were assigned to receive sacubitril–valsartan and 2831 to receive ramipril. Over a median of 22 months, a primary-outcome event occurred in 338 patients (11.9%) in the sacubitril–valsartan group and in 373 patients (13.2%) in the ramipril group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.17). Death from cardiovascular causes or hospitalization for heart failure occurred in 308 patients (10.9%) in the sacubitril–valsartan group and in 335 patients (11.8%) in the ramipril group (hazard ratio, 0.91; 95% CI, 0.78 to 1.07); death from cardiovascular causes in 168 (5.9%) and 191 (6.7%), respectively (hazard ratio, 0.87; 95% CI, 0.71 to 1.08); and death from any cause in 213 (7.5%) and 242 (8.5%), respectively (hazard ratio, 0.88; 95% CI, 0.73 to 1.05). Treatment was discontinued because of an adverse event in 357 patients (12.6%) in the sacubitril–valsartan group and 379 patients (13.4%) in the ramipril group.

CONCLUSIONS
Sacubitril–valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction. (Funded by Novartis; PARADISE-MI ClinicalTrials.gov number, NCT02924727. opens in new tab.)
Original languageEnglish
Pages (from-to)1845-1855
Number of pages11
JournalNew England Journal of Medicine
Volume385
Issue number20
DOIs
Publication statusPublished - 11 Nov 2021

Fingerprint

Dive into the research topics of 'Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction'. Together they form a unique fingerprint.

Cite this